| 1 |
IND Approval of Novel Immunotherapy for NHL: Intratumoral Administration of Novel Adjuvant ProLNG-001 and/or Personalized Cancer Vaccine ProV-001 |
| Other-Bio. |
non-Hodgkin lymphoma |
BCR 가변영역 |
Preclinical |
Progeneer Inc. |
RS-2025-02122974 |
|
| 2 |
Develop Anti-Cancer Therapeutics for HER2 low Gastric Cancers by Combining Targeting Peptide and NanoCarrier |
| Other-Bio. |
HER2 low Gastric Cancer |
HER2 |
Candidate |
KMD Bio Ltd |
RS-2024-00333872 |
|
| 3 |
Development of a lead compound for anti-cancer drug using immunoactive attenuated Salmonella |
| Other-Bio. |
Solid Tumor |
FlaB, ClyA |
Lead |
CNCure biotech Inc. |
RS-2022-00167101 |
|
| 4 |
Candidate development of individualized cancer vaccine for the non-Hodgkin Lymphoma |
| Other-Bio. |
Non-Hodgkin lymphoma |
Non-Hodgkin Lymphoma |
Candidate |
Progeneer |
RS-2022-00166284 |
|
| 5 |
Development of therapeutic autologous vaccine against acute myeloid leukemia |
| Other-Bio. |
AML |
αGC-loaded ECNV of AML |
Hit |
Seoul National University |
RS-2022-00165569 |
|
| 6 |
Development of a combination therapy for colorectal cancer using attenuated Salmonella and anti-PD-L1 antibody |
| Other-Bio. |
Colorectal cancer |
Colorectal cancer (late stage) patients |
Candidate |
CNCure biotech Inc. |
HN22C0637 |
|
| 7 |
Development and optimization of a new form factor for next-generation cancer immunotherapy |
| Other-Bio. |
Solid Tumor |
DCs |
Hit |
Yonsei University |
HN21C1410 |
|
| 8 |
Lead development study on exosomes with anticancer potential armed with FAF1, a multifunctional tumor suppressor and a genuine exosome cargo |
| Other-Bio. |
Pancreatic cancer, Liver cancer |
FAF1 |
Lead |
ChungNam National University |
HN21C0048 |
|